c="COL5A2" 1:5 1:5||t="test"||cui="C1413588"||tot="COL5A2 gene"||ns="-1000"
c="Ehlers-Danlos syndrome type II" 1:7 1:10||t="problem"||cui="C0268336"||tot="Ehlers-Danlos syndrome, type 2"||ns="-1000"
c="Ehlers-Danlos syndrome (EDS" 2:0 2:2||t="problem"||cui="C0013720"||tot="Ehlers-Danlos Syndrome"||ns="-1000"
c="affected subject synthesised abnormal type V collagen" 2:57 2:63||t="treatment"||cui="C0009335"||tot="Collagen Type V"||ns="-845"
c="Haplotype analysis" 2:64 2:65||t="test"||cui="C0002778"||tot="Analysis of substances"||ns="-861"
c="COL5A1" 2:67 2:67||t="test"||cui="C1413587"||tot="COL5A1 gene"||ns="-1000"
c="COL5A2" 2:72 2:72||t="test"||cui="C1413588"||tot="COL5A2 gene"||ns="-1000"
c="disease locus" 2:75 2:76||t="test"||cui="C1708726"||tot="Locus"||ns="-861"
c="other collagens" 2:116 2:117||t="treatment"||cui="C0009325"||tot="Collagen"||ns="-861"
